Adimab Collaborator GSK Receives Additional Marketing Approval for Depemokimab

Depemokimab is the first ultra-long-acting biologic product approved for use in its indicated conditions.

Apr. 15, 2026 at 4:21pm

Got story updates? Submit your updates here. ›

A highly textured, abstract painting in muted earth tones depicting the complex molecular structure and engineering of a new biologic antibody therapy, conveying the scientific innovation behind this breakthrough treatment.Adimab's antibody engineering expertise enables partners like GSK to develop innovative biologic therapies with extended half-life and enhanced binding affinity.Lebanon Today

Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, congratulates GSK plc for recently receiving approvals by the European Commission (EC) and China's National Medical Products Administration (NMPA) for depemokimab. This adds to recent marketing approvals in the United States, Japan, and the United Kingdom. Depemokimab was developed internally by GSK with an extended half-life and engineered high binding affinity to enable twice-yearly dosing, as demonstrated in GSK's pivotal trials.

Why it matters

Depemokimab is the first approved product to emerge from Adimab's Platform Transfer collaborations, further validating this portion of Adimab's business model. GSK was Adimab's first Platform Transfer collaborator, and this success demonstrates the value of Adimab's technology in enabling partners to pursue innovative therapeutic products.

The details

To support the engineering of depemokimab, GSK internalized Adimab's proprietary yeast-based technology, enabling in-house antibody discovery, optimization, production, and characterization on any target of GSK's choosing. GSK's research team used the Adimab Platform to develop depemokimab, a product tailored to meet GSK's target product profile, including low picomolar affinity. GSK continues to use the Adimab platform to support other internal programs.

  • Adimab and GSK announced the approvals for depemokimab in the European Union and China on April 15, 2026.
  • Depemokimab had previously received marketing approvals in the United States, Japan, and the United Kingdom.

The players

Adimab, LLC

The global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies.

GSK plc

A multinational pharmaceutical company that developed depemokimab using Adimab's proprietary technology.

Philip T. Chase

The Chief Executive Officer of Adimab.

Eric Krauland

The President and Chief Scientific Officer of Adimab.

Got photos? Submit your photos here. ›

What they’re saying

“Depemokimab is the first approved product to emerge from our Platform Transfer collaborations, further validating this portion of our business model. Fittingly, GSK was our first Platform Transfer collaborator, and we congratulate them on this tremendous success.”

— Philip T. Chase, Chief Executive Officer of Adimab

“Depemokimab is just one example of GSK's adoption of the Adimab technology to pursue innovative therapeutic products. GSK's use of the platform, exemplified through ongoing investment in the Adimab team's expertise and the use of Adimab's technological advances such as new library diversities, has translated into other GSK clinical programs that aim to make a real difference for patients.”

— Eric Krauland, President and Chief Scientific Officer of Adimab

The takeaway

Adimab's proprietary antibody discovery and engineering platform has enabled its partners, like GSK, to develop innovative biologic therapies that can make a significant impact on patient care. The success of depemokimab demonstrates the value of Adimab's technology transfer model in empowering its collaborators to pursue novel treatments in-house.